- Home
- IR vs RPRX Comparison
IR vs RPRX Comparison
Compare IR & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IR | RPRX |
|---|---|---|
| Founded | 1859 | 1996 |
| Country | United States | United States |
| Employees | N/A | 100 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.6B | 27.1B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IR | RPRX |
|---|---|---|
| Price | $77.76 | $61.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $94.71 | $65.38 |
| AVG Volume (30 Days) | ★ 4.2M | 2.6M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | 0.10% | ★ 1.58% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.15 | 0.71 |
| Revenue | $2,375,400,000.00 | ★ $2,378,193,000.00 |
| Revenue This Year | $6.09 | $47.38 |
| Revenue Next Year | $4.95 | $8.97 |
| P/E Ratio | ★ $67.66 | $83.96 |
| Revenue Growth | ★ 22.48 | 5.06 |
| 52 Week Low | $68.07 | $35.92 |
| 52 Week High | $100.96 | $64.38 |
Technical Indicators
Market Signals| Indicator | IR | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.94 | 62.85 |
| Support Level | $75.10 | $55.04 |
| Resistance Level | $84.36 | $64.38 |
| Average True Range (ATR) | 2.01 | 1.19 |
| MACD | 0.24 | 0.42 |
| Stochastic Oscillator | 52.61 | 94.41 |
Price Performance
Historical ComparisonAbout IR Ingersoll Rand Inc.
Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.7 billion in revenue in 2025.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.